EMV Capital, the VC investor specialising in high-growth deep tech and life sciences companies, has reported interim results for the six months to 30th June 2025, with revenues of £1.1 million, slightly down from £1.2m a year earlier, and losses reduced to £1.5m from £1.8m.

Total assets grew to £19.7m from £19.5m at the end of FY 2024, though net assets slipped to £13.6m from £14.1m. Cash fell to £0.5m from £1.0m, alongside a reduction in readily realisable securities to £1.0m from £2.5m.

Assets under management remained strong at £104.7m, compared to £106.7m in H1 2024, with £5m syndicated into seven portfolio companies, down from £6.4m into 11 companies.

CEO Dr Ilian Iliev said the group remains focused on expanding its funds practice and delivering shareholder value despite challenging markets.